Rein Therapeutics presents late-breaking ERS poster on inhaled LTI-03 idiopathic pulmonary fibrosis dose-escalation trial - RNTX News | RalliesRein Therapeutics presents late-breaking ERS poster on inhaled LTI-03 idiopathic pulmonary fibrosis dose-escalation trial
R
RNTX• ERS poster presentation on LTI-03
- Rein Therapeutics will present a late-breaking ERS 2026 poster on inhaled LTI-03 in idiopathic pulmonary fibrosis on Sept. 8.
- Results were already published in Nature Communications; the ERS presentation will bring the findings to a major medical meeting audience.
- The randomized dose-escalation study supports continued clinical development of LTI-03 in pulmonary fibrosis, an orphan market with high unmet need.
•
